Comment on Novartis Heart Failure Drug Tops Standard in Study - Businessweek

Novartis Heart Failure Drug Tops Standard in Study - Businessweek

MiamiHerald.comNovartis Heart Failure Drug Tops Standard in StudyBusinessweekNovartis AG (NOVN)'s experimental heart failure drug kept more patients in a study from dying or being hospitalized than the standard therapy, a result that could transform treatment of the disease that afflicts 26 million people worldwide. In a trial involving ...Novartis Study Shows New Heart Drug Cuts Cardiovascular DeathsWall Street JournalNew Heart Drug Saves More Lives Than Standard TreatmentTIMENew Novartis Drug Shows Striking Efficacy in Treating Heart FailureNew York TimesForbes -RTT News -Reuters UKall 16 news articles »

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News